Tissue kallikrein (KLK1) is a kinin-forming serine protease synthesized in many organs including arteries and kidney. Study of the physiological role of KLK1 has benefited from the availability of mouse and human genetic models of KLK1 deficiency, through engineering of KLK1 mouse mutants and discovery of a major polymorphism in the human KLK1 gene that induces a loss of enzyme activity. Studies in KLK1-deficient mice and human subjects partially deficient in KLK1 have documented its critical role in arterial function in both species. KLK1 is also involved in the control of ionic transport in the renal tubule, an action that may not be kinin-mediated. Studies of experimental diseases in KLK1-deficient mice have revealed cardio-and nephro-protective effects of KLK1 and kinins in acute cardiac ischemia, post-ischemic heart failure, and diabetes. Potential clinical and therapeutic developments are discussed.
Introduction
Tissue kallikrein (KLK1) is a serine protease displaying favourable kinetic parameters for hydrolysis of kininogens, and is a major kinin-forming enzyme in mammals. The pharmacological effects of kinins have been well described at the systemic and cellular levels, and their target organs have been identified (Bhoola et al., 1992) . Kinins are especially active on the vascular endothelium, where they trigger release of several paracrine and autocrine mediators, such as NO, prostanoids and leukotrienes, and so-called hyperpolarizing factors, which promote smooth muscle cell relaxation and inhibit platelet adhesion and aggregation (Leeb-Lundberg et al., 2005) . Through the action of these mediators, kinins are potent vasodilators and inhibitors of blood coagulation. In addition, kinins promote fibrinolysis by stimulating release of tissue plasminogen activator from the endothelium (Brown et al., 2000) .
However, it is still largely unknown whether kinins are released in vivo at tissue sites and in the circulation and are involved in the control of homeostasis. The physiological role of endogenously produced kinins has been probed indirectly using angiotensin-converting enzyme (ACE, kininase II, a major kinin-inactivating enzyme) inhibitors, and directly using kinin receptor antagonists and, more recently, kinin B2 receptor-deficient mice (Borkowski et al., 1995; Linz et al., 1995) . These pharmacological and genetic tools have provided valuable information, alone and in combination with ACE inhibitors, especially in pathological situations. However, kinins act on two types of receptors, B1 and B2. The B2 receptor is constitutively synthesized in tissues, contrary to the B1 receptor, and is generally considered as being the receptor involved in the main effects of kinins in healthy animals, including the vascular effects (Leeb-Lundberg et al., 2005) . But there is now evidence that the B1 receptor is induced in the absence of the B2 receptor and takes over functions of the latter, at least in arteries and heart (Duka et al., 2001; Griol-Charhbili et al., 2005) . Thus, the role of kinins in homeostasis cannot be fully assessed using B2 receptor-deficient mice. In addition, the mechanisms of kinin formation in tissues and the regulation of this formation cannot be followed at the receptor level.
Recently, murine and human genetic models of KLK1 deficiency have become available through engineering of KLK1 mouse mutants and discovery of a major polymorphism of the human KLK1 gene that induces a loss of enzyme activity Slim et al., 2002) . Studies of kinin formation in KLK1-deficient mice indicated that KLK1 is the main kinin-forming enzyme in most organs, including arteries and kidney, in normal animals Meneton et al., 2001) . Physiological studies in KLK1-deficient mice and in human subjects partially deficient in KLK1 have revealed the critical role of KLK1 in arterial function in both species. Studies of experimental diseases in KLK1-deficient mice have identified a cardioprotective role of KLK1 and kinins in acute cardiac ischemia and post-ischemic heart failure, and a nephroprotective role of KLK1 in diabetes. In addition, study of kidney function in KLK1-deficient mice and man has suggested that KLK1 participates in the control of ionic transport in the renal tubule, and that this action may not be kinin-mediated.
KLK1 gene inactivation in the mouse
Disruption of the KLK1 gene in the mouse results in a G95% reduction in kinin-forming activity on kininogen in kidney, colon, pancreas, and salivary glands of homozygous KLK1-deficient mice (KLK1 -/-mice). For the salivary gland, which has 100-to 1000-fold more kininforming activity than the other organs, 98% suppression of activity was observed in KLK1 -/-mice, despite high abundance of several other proteases of the kallikrein family in this organ. In kidney, pancreas and urine, kininforming activity is virtually absent in KLK1 -/-mice and is 30-40% of the wild-type level in heterozygous animals. These observations suggest that in healthy animals, KLK1 is the main kinin-forming enzyme in these organs and is probably the only one of physiological relevance .
The KLK1 gene is expressed in arteries of wild-type mice. When the carotid artery of these mice was perfused with kininogen, vasodilatation was observed that was abolished by a kinin B2 receptor antagonist. In KLK1-deficient mice, however, kininogen no longer dilated the artery ). These observations document the presence and functionality of KLK1 in arteries and suggest that KLK1 is the sole kinin-forming enzyme synthesized by these vessels.
Deficiency in KLK1 activity in humans
Early work suggested that the large inter-individual variability in urinary KLK1 (uKLK1) activity in man reflected, at least in part, a genetic polymorphism of this activity. Family studies revealed familial aggregation of uKLK1, and proposed a transmission model for uKLK1, with a major gene effect accounting for almost half of the variance of the trait (Zinner et al., 1976; Berry et al., 1989) . However, the molecular basis of the genetic polymorphism of uKLK1 remained unknown.
When the KLK1 gene on chromosome 19q13.2-q13.4 was studied, it was found that this gene and its promoter were highly polymorphic. A complex, multi-allelic promoter variation has been considered to be a candidate for the genetic polymorphism of uKLK1, because this promoter variation was reported to be associated with blood pressure level, an observation also made for uKLK1 in the family transmission studies (Yu et al., 2002) . However, association of this promoter variation with uKLK1 has not been reported. On the other hand, several single nucleotide polymorphisms were identified in the coding sequence of the KLK1 gene, in the promoter and the first intron (Slim et al., 2002) . Two of these sequence variations are non-synonymous substitutions in exon 3 and change an amino acid in KLK1, either in position 53 (the minor allele coding for histidine instead of arginine) or in position 121 (glutamate instead of glutamine). Interestingly, the R53H polymorphism was associated with a decrease of approximately 50% in uKLK1 in several populations in which only heterozygote subjects were identified. Furthermore, when recombinant kallikrein variants were synthesized, the R53H variant displayed a defect in enzyme activity. This defect was substrate-dependent, but very pronounced for hydrolysis of kininogen, with residual kinin-forming activity of -1% of the activity of the wild-type enzyme (Slim et al., 2002) .
KLK1 has an extended active site compared to other kallikrein-related proteases that allows it to accommodate kininogens. Construction of a molecular model based on crystallographic data suggests that the arginine in position 53 is located in a putative kininogen-binding subsite in the active site. This suggests a mechanistic hypothesis for the inactivating effect of the R53H mutation, which alters molecular structure and electrostatic charge at this subsite. On the other hand, the Q121E mutation was not associated with any significant variation in KLK1 activity, either in vitro or in vivo. The amino acid in position 121 is located on the opposite side of the molecule to the active site (Slim et al., 2002) .
The allelic frequency of the R53H mutation is 0.03 in European and 0.07 in African-Caribbean populations. This implies that in European and North American populations, 6-7% of subjects are heterozygous for this mutation (Slim et al., 2002) . Homozygous 53H subjects should account for approximately 1:2000 individuals in these populations, and none have been available for study so far. Because of its low frequency, the R53H mutation is unlikely to account for all of the genetic polymorphism of uKLK1, which was estimated to account for more than 50% of the variance of uKLK1 in familial transmission studies (Berry et al., 1989) . Other genetic variations in KLK1 or other genes that are as yet unidentified may also be involved. However, other polymorphisms identified in KLK1 were not associated with uKLK1, except for promoter variations that were in linkage disequilibrium with the R53H polymorphism. In any case, R53H subjects, with a 50% decrease in KLK1 activity, can be studied to probe the physiological role of KLK1 in humans and to determine the consequences of partial genetic deficiency in KLK1.
Arterial dysfunction in KLK1-deficient mice and humans
KLK1-deficient mice have normal blood pressure at rest, but arterial function is impaired in these mice, with abnormal vasomotor response to blood flow. The mice display a major defect in flow-dependent vasodilatation, a fundamental feature of arterial physiology that ensures proper delivery of blood to tissues. At high blood flow, vasodilatation is decreased by 40% in KLK1 -/-mice, whereas at low flow a paradoxical vasoconstrictor response to flow increase is observed Meneton et al., 2001 ). This defect is observed in both capacitance and resistance arteries (Hilgers et al., 2003; Bergaya et al., 2004b) . Flow-mediated vasodilatation is an endothelium-dependent process, and these observations are indicative of endothelial dysfunction in KLK1-deficient mice, even if the vasodilator response to exogenous acetylcholine is not altered (Bergaya et al., , 2004a . Interestingly, heterozygote mice with only partial deficiency of KLK1 also exhibited a defect in flowdependent vasodilatation, an observation suggesting that the level of KLK1 is a determinant of arterial function .
To test extrapolation of these mouse findings to man, the brachial artery of young human subjects carrying a mutated R53H allele and partially deficient in KLK1 was studied non-invasively. These subjects, like the KLK1-deficient mice, exhibited arterial abnormalities (Azizi et al., 2005) . Although flow-dependent dilatation was not grossly impaired, shear stress was increased. Moreover, although elevated shear stress should induce vasodilatation, a paradoxical narrowing of the artery lumen was observed (Azizi et al., 2005) . These functional abnormalities are suggestive of endothelial dysfunction, even if, as in the mouse, the vasodilator response to exogenous acetylcholine was not altered (Azizi et al., 2005; Rossi et al., 2006) . These observations document the occurrence of a new mild form of arterial dysfunction in heterozygous subjects carrying the R53H KLK1 mutation. As discussed above, these subjects represent a significant subset (7%) of European and North American populations.
These studies demonstrate that KLK1 is involved in arterial function in both mouse and man. Whereas KLK1 levels are low in arteries compared to several other organs that synthesize KLK1, the role of KLK1 appears to be critical for arterial function. The action of KLK1 in artery is most likely kinin-and B2 receptor-mediated. The mechanism linking flow to KLK1 remains poorly understood. As the vasomotor response to flow occurs quickly, an effect on KLK1 gene transcription and KLK1 synthesis is unlikely, at least initially. An increase in shear stress may trigger addressing of KLK1 to the endothelial cell surface, where it can access its substrate, kininogen, which is present in plasma and adsorbed on endothelial cell surfaces (Hasan et al., 1995) . Shear stress may also increase the accessibility of kinins to endothelial B2 receptors.
In any case, the arterial dysfunction of R53H subjects may increase their risk of developing cardiovascular diseases with aging or in pathological settings such as diabetes. This hypothesis needs to be tested in population studies. Study of the KLK1-deficient mouse may also provide information relevant to a putative causal link between KLK1 deficiency and cardiovascular diseases. This has been the case so far for ischemic heart disease.
Effects of KLK1 deficiency in the normal and ischemic heart
The heart of KLK1-deficient mice is either normal or exhibits minor functional and trophic abnormalities, depending on the genetic background. On a mixed 129sv-C57BL6 background, mostly 129sv, the heart exhibits mild thinning of the septum and posterior wall and a tendency to dilatation in comparison to wild-type littermates . When the KLK1 geneinactivating mutation was developed on a pure C57BL6 background, however, the heart did not exhibit any functional or trophic abnormality (Trabold et al., 2002) . A similar differential effect of these two genetic backgrounds on cardiac phenotype has been observed for B2 receptor-deficient mice (Madeddu et al., 2007) . Mice of the 129 strain have two renin genes, contrary to those of the C57BL6 strain, which have only one renin gene. It has been hypothesized that activation of the renin-angiotensin system explains enhanced blood pressure and cardiac sensitivity to physiological stimulus in 129 mice (Wang et al., 2002) , although this has not been consistently observed (Gurley et al., 2006) . Blood pressure in KLK1-deficient mice is normal on all genetic backgrounds studied. It may nevertheless be speculated that the coronary arteries of KLK1-deficient mice have, like other arteries, endothelial dysfunction, resulting in abnormal regulation of coronary blood flow and subsequent cardiac adaptation and remodeling, since the heart is a permanently working organ that is highly sensitive to blood supply. However, dysregulation of coronary blood flow may remain moderate under basal conditions and cardiac remodeling is only observed on a permissive genetic background.
In the C57BL6 strain with one renin gene, the heart of KLK1 -/-mice is morphologically and functionally indistinguishable from the heart of wild-type littermates. This strain was thus used to study experimental cardiac diseases, allowing straightforward interpretation of the effect of KLK1 mutation on disease-related phenotypes.
In the setting of acute cardiac ischemia and ischemia reperfusion injury, KLK1-deficient mice exhibit a defect in cardioprotective mechanisms preventing necrosis, as evidenced by a severe decrease in the beneficial effect of ischemic preconditioning (Griol-Charhbili et al., 2005) . Ischemic preconditioning is an experimental maneuver consisting of repeated short cycles of ischemia reperfusion before inducing prolonged ischemia. It activates a number of cardiac protective mechanisms, which are only partly understood, resulting in infarct size reduction. Although the clinical relevance of ischemic preconditioning cannot be established easily, this phenomenon is believed to occur in man in coronary insufficiency and to play a significant role in disease outcome, protecting against myocardial infarction. KLK1-deficient mice exhibited a 40% decrease in the effect of ischemic preconditioning (Griol-Charhbili et al., 2005) . In addition, in the setting of acute cardiac ischemia and ischemia-reperfusion injury, the well-documented infarct size-limiting effect of ACE inhibitors and of angiotensin II AT1 receptor antagonists is almost completely suppressed in KLK1-deficient mice (Griol-Charhbili et al., 2005; Messadi-Laribi et al., 2007) . These data indicate that the cardioprotective effect of these drugs in acute cardiac ischemia in mouse requires KLK1, and is mainly, if not entirely, mediated by kinins. The hypothesis of a prominent role of kinins in the cardioprotective effects of ACE inhibitors relies on a wellestablished physiological pathway (inactivation of kinins by ACE) and has been previously documented using B2 receptor antagonists and B2 receptor-deficient mice (Linz et al., 1995; Yang et al., 2001) , but the role of KLK1 in the effect of angiotensin II AT1 receptor antagonists appears more surprising. This issue is discussed below.
In post-ischemic heart failure induced by coronary ligature and myocardial infarction, KLK1 deficiency is also detrimental. It aggravates cardiac remodeling and decreases survival, especially after several months of evolution (Pons et al., 2008) .
Overall, these studies point to a major cardioprotective role of KLK1 in acute cardiac ischemia and heart failure. The effect of KLK1 deficiency can be mimicked by B2 receptor blockade, at least in acute ischemia (Griol-Charhbili et al., 2005) , and therefore the effects of KLK1 in the ischemic heart are most probably kinin-mediated. Kinins influence coronary perfusion, cardiac metabolism and redox status (Oldenburg et al., 2004) . In post-ischemic heart failure, NO synthase isoforms seem to be involved in KLK1 and kinin effects (Pons et al., 2008) . These studies establish KLK1 as the major kinin-forming enzyme in the ischemic heart. The observations in KLK1-deficient mice raise the hypothesis that KLK1-deficient subjects may be at increased risk of myocardial infarction in coronary heart disease, with poorer prognosis in heart failure. This hypothesis needs to be tested in clinical studies. It is of interest that the well-documented genetic polymorphism of ACE levels has been linked to the risk of myocardial infarction (Cambien et al., 1992 (Cambien et al., , 1994 . As high ACE levels, like KLK1 deficiency, induce kinin depletion, the observation of a loss of the beneficial effect of ischemic preconditioning in KLK1-deficient mice suggests a mechanistic hypothesis for the association of ACE levels with myocardial infarction risk. Indeed, a preliminary study indicated that in mice bearing a duplication of the ACE gene, the effect of ischemic preconditioning was suppressed (Richer and Alhenc-Gelas, unpublished data).
Role of KLK1 in the cardiovascular effects of angiotensin II AT2 receptor stimulation
Although the angiotensin II AT2 receptor is involved in flow-dependent dilatation in normal mice and its inhibition impairs relaxation, in KLK1 -/-mice this receptor is normally present, but its inhibition has no effect (Bergaya et al., 2004a) . Conversely, inhibition of the B2 receptor reduces flow-dependent dilatation in normal mice, but has no effect in AT2 receptor-deficient mice. These observations suggest a functional coupling between the AT2 receptor and KLK1 and kinins in arteries. Coupling between the AT2 and B2 receptors has previously been proposed in the kidney, heart and arteries on the basis of pharmacological experiments with B2 receptor antagonists that suppressed some of the effects of AT1 receptor blockade, a maneuver that induces AT2 receptor stimulation (Gohlke et al., 1998; Sato et al., 2000; Siragy et al., 2000) . However, the mechanism of this physiological coupling remains unclear, and both kinin-and nonkinin-mediated mechanisms have been postulated (Abadir et al., 2006; Messadi-Laribi et al., 2007) . Studies in KLK1-deficient mice indicate that KLK1 is involved in the coupling between AT2 and B2 receptors in arteries (Bergaya et al., 2004a) . Observations in the ischemic heart during AT1 receptor blockade (see above, MessadiLaribi et al., 2007) also support the hypothesis that AT2 receptor stimulation triggers kinin formation by KLK1 and subsequent B2 receptor activation. KLK1 might also directly activate the B2 receptor (Hecquet et al., 2000) .
Thus, the renin angiotensin system is positively coupled to the tissue kallikrein-kinin system through the AT2 receptor. This pathway is activated when AT1 receptor function is suppressed, and is involved in arterial vasodilatation and in cardioprotection during ischemia. The physiological role of the AT2-KLK1-B2 pathway in the presence of a functional AT1 receptor remains to be established.
Effect of KLK1 deficiency in the kidney: kinin-and non-kinin-mediated effects
KLK1 in renal arteries is likely to participate in the control of renal hemodynamics. However, KLK1 is also synthesized in abundance in renal epithelial cells in the distal tubule and is secreted in urine. The function of epithelial KLK1 in the kidney remains unknown. In a systematic study of water and electrolyte metabolism, it was observed that KLK1-deficient mice displayed hypercalciuria of renal origin and were unable to maintain normal plasma calcium level when submitted to a calcium-poor regimen because of persistent urinary calcium loss (Picard et al., 2005) . Interestingly, the renal calcium defect of KLK1-deficient mice was not observed in B2 receptor-deficient mice, even after treatment with a B1 receptor antagonist (Picard et al., 2005) . This suggests a non-kinin-mediated mechanism for the effect of KLK1 on calcium reabsorption. A proteolytic effect of KLK1 on proteins involved in calcium transport in distal tubular cells can be hypothesized. Proteolytic regulation of electrolytes transport in the kidney tubule has already been documented for other proteases (Vallet et al., 1997) . KLK1 partly co-localizes with the calcium transporter TRPV5 in the distal tubule (Picard et al., 2005) . In primary culture of renal calcium-transporting epithelial cells, KLK1 is able to increase calcium reabsorption by stabilizing TRPV5 on the plasma membrane. However, this in vitro effect of KLK1 has been reported to be kinin-and B2 receptor-mediated (Gkika et al., 2006) . Thus, although observations in KLK1-deficient mice indicate that renal KLK1 is involved in calcium reabsorption in the distal tubule, it is not clear at present whether this action is direct or kinin-mediated or both. Recent data obtained in KLK1-deficient mice also suggest that KLK1 is involved in proteolytic regulation of the sodium channel Enac in the renal tubule (Picard et al., 2008) . The involvement of KLK1 in renal calcium metabolism has been confirmed in man by studying partially KLK1-deficient subjects. A minor defect in renal calcium reabsorption, evidenced by furosemide administration, has indeed been observed in these subjects (Blanchard et al., 2007) .
A circulating form of KLK1 is present in plasma. Although plasma KLK1 in mouse is believed to originate mainly from the salivary glands, which are well developed in this species, indirect evidence suggests that plasma KLK1 in man originates mainly from the kidney (Azizi et al., 2008) . Plasma KLK1 is regulated by sodium and potassium intake. The role of this endocrine component of the renal kallikrein-kinin system in the control of homeostasis remains unknown. KLK1 irreversibly binds protease inhibitors in plasma (Zhou et al., 1992) . However, this binding is a slow process, and before inactivation plasma KLK1 may produce kinins near its secretion site, or at distance, although this is speculative.
An investigation of experimental renal diseases in KLK1-deficient mice is currently in progress. KLK1 deficiency aggravates diabetic nephropathy (Bodin, Alhenc-Gelas and Bouby, unpublished data). This observation is in agreement with previous studies documenting aggravation of the disease in mice bearing a duplication of the ACE gene ) and in those with inactivation of the B2 receptor gene (Kakoki et al., 2006) . Kinins seem to play a major role in protection against organ damage in the kidney and the cardiovascular system in the setting of diabetes.
Conclusions
The availability of mutant mice and human subjects genetically deficient in KLK1 activity has allowed recognition of the importance of KLK1 and its kinin peptide products in arterial function in both species, which was largely unsuspected from previous studies. KLK1 appears to be the major kinin-forming enzyme in arteries, heart and kidney. The KLK1-deficient mouse can be considered practically as a kinin-free mouse, at least in normal condition and in the pathological situations studied, cardiac ischemia and insulin-dependent diabetes. In these pathological situations, the tissue kallikrein-kinin system is involved in heart and kidney protection and its absence aggravates cardiac necrosis and renal damage. The clinical relevance of observations in KLK1-deficient mice can be tested by studying cardiac and renal diseases in partially KLK1-deficient human subjects.
Studies have also documented the involvement of KLK1 in the regulation of electrolyte transport in the kidney tubule, but in this case KLK1 action may not be kinin-mediated. The recent availability of mice with combined inactivation of the B1 and B2 receptors (Cayla et al., 2007; Kakoki et al., 2007) may help to clarify the issue of kinin-versus non-kinin-mediated physiological action of KLK1.
Data obtained in mouse and man deficient in KLK1 further support the concept of the kallikrein-kinin system as a promising therapeutic target. Therapeutic activation of this system is currently achieved indirectly and only mildly using ACE inhibitors or angiotensin II AT1 receptor antagonists, an approach that is efficacious in a number of cardiovascular and renal diseases. However, the therapeutic efficacy of ACE inhibitors and AT1 receptor blockers is probably restricted by the limited availability of endogenous KLK1 and kinins. The design and evaluation of more potent pharmacological interventions based on kinin receptor agonism are warranted.
